127 related articles for article (PubMed ID: 27778096)
1. The dimeric form of HLA-G molecule is associated with the response of early rheumatoid arthritis (ERA) patients to methotrexate.
Rizzo R; Farina I; Bortolotti D; Galuppi E; Padovan M; Di Luca D; Govoni M
Clin Rheumatol; 2017 Mar; 36(3):701-705. PubMed ID: 27778096
[TBL] [Abstract][Full Text] [Related]
2. HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis.
Rizzo R; Rubini M; Govoni M; Padovan M; Melchiorri L; Stignani M; Carturan S; Ferretti S; Trotta F; Baricordi OR
Pharmacogenet Genomics; 2006 Sep; 16(9):615-23. PubMed ID: 16906016
[TBL] [Abstract][Full Text] [Related]
3. Association of
Gautam S; Kumar U; Kumar M; Kanga U; Dada R
Immunol Invest; 2020 Feb; 49(1-2):88-105. PubMed ID: 31549885
[No Abstract] [Full Text] [Related]
4. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
[TBL] [Abstract][Full Text] [Related]
5. MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients.
Micsik T; Lőrincz A; Gál J; Schwab R; Peták I
Diagn Pathol; 2015 Dec; 10():216. PubMed ID: 26715450
[TBL] [Abstract][Full Text] [Related]
6. The paradox of high availability and low recognition of soluble HLA-G by LILRB1 receptor in rheumatoid arthritis patients.
Veit TD; Chies JA; Switala M; Wagner B; Horn PA; Busatto M; Brenol CV; Tavares Brenol JC; Machado Xavier R; Rebmann V
PLoS One; 2015; 10(4):e0123838. PubMed ID: 25853899
[TBL] [Abstract][Full Text] [Related]
7. CD39 positive regulatory T cell frequency as a biomarker of treatment response to methotrexate in rheumatoid arthritis.
Gupta V; Katiyar S; Singh A; Misra R; Aggarwal A
Int J Rheum Dis; 2018 Aug; 21(8):1548-1556. PubMed ID: 30146748
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
[TBL] [Abstract][Full Text] [Related]
9. HLA-G may predict the disease course in patients with early rheumatoid arthritis.
Rizzo R; Farina I; Bortolotti D; Galuppi E; Rotola A; Melchiorri L; Ciancio G; Di Luca D; Govoni M
Hum Immunol; 2013 Apr; 74(4):425-32. PubMed ID: 23228398
[TBL] [Abstract][Full Text] [Related]
10. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
[TBL] [Abstract][Full Text] [Related]
11. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
Iwamoto N; Kawakami A; Fujikawa K; Aramaki T; Kawashiri SY; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Goto A; Fukuda T; Matsuoka N; Ueki Y; Tsukada T; Migita K; Shoumura F; Kawabe Y; Shibatomi K; Mine M; Ida H; Origuchi T; Aoyagi K; Eguchi K
Mod Rheumatol; 2009; 19(5):488-92. PubMed ID: 19578932
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Müller RB; von Kempis J; Haile SR; Schiff MH
Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate.
Patro PS; Singh A; Misra R; Aggarwal A
J Rheumatol; 2016 Apr; 43(4):731-7. PubMed ID: 26834220
[TBL] [Abstract][Full Text] [Related]
15. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Van der Elst K; Meyfroidt S; Westhovens R;
Arthritis Res Ther; 2015 Apr; 17(1):97. PubMed ID: 25889222
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
17. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
Heimans L; Wevers-de Boer KV; Visser K; Goekoop RJ; van Oosterhout M; Harbers JB; Bijkerk C; Speyer I; de Buck MP; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
Ann Rheum Dis; 2014 Jul; 73(7):1356-61. PubMed ID: 23716067
[TBL] [Abstract][Full Text] [Related]
18. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.
O'Dell JR; Elliott JR; Mallek JA; Mikuls TR; Weaver CA; Glickstein S; Blakely KM; Hausch R; Leff RD
Arthritis Rheum; 2006 Feb; 54(2):621-7. PubMed ID: 16447240
[TBL] [Abstract][Full Text] [Related]
19. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
[TBL] [Abstract][Full Text] [Related]
20. Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate.
Varani K; Massara A; Vincenzi F; Tosi A; Padovan M; Trotta F; Borea PA
Arthritis Rheum; 2009 Oct; 60(10):2880-91. PubMed ID: 19790066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
